SOURCE: Novo Nordisk A/S

November 02, 2009 10:05 ET

Transaction in Own Shares

BAGSVAERD, DENMARK--(Marketwire - November 2, 2009) - Novo Nordisk A/S - Share repurchase programme

On 7 August 2009 Novo Nordisk initiated its share repurchase programme in accordance with the provisions of the European Commission's regulation no 2273/2003 of 22 December 2003, also referred to as the Safe Harbour rules.

Under the programme Novo Nordisk will repurchase B shares for an amount up to DKK 2.4 billion in the period from 10 August 2009 to 18 December 2009.

Since the announcement as of 26 October 2009, the following transactions have been made under the programme:

                  Number of    Average     Transaction value,
                   shares   purchase price        DKK
Accumulated, last
announcement      4,222,050                     1,347,733,822
26 October 2009      52,950       323.8990         17,150,452
27 October 2009      77,500       324.4390         25,144,023
28 October 2009      75,000       327.1799         24,538,493
29 October 2009     151,599       314.7490         47,715,634
30 October 2009      90,000       313.7299         28,235,691
Accumulated under
 the programme    4,669,099                     1,490,518,113

Transactions related to Novo Nordisk's incentive programmes have resulted in a net sale by Novo Nordisk of 29,080 B shares in the period from 29 October 2009 to 30 October 2009. The shares in these transactions were not part of the Safe Harbour repurchase programme.

With the transactions stated above, Novo Nordisk owns a total of 29,476,827 treasury shares, corresponding to 4.8% of the share capital. The total amount of shares in the company is 620,000,000 including treasury shares.

Novo Nordisk is a healthcare company and a world leader in diabetes care. In addition, Novo Nordisk has a leading position within areas such as haemostasis management, growth hormone therapy and hormone replacement therapy. Novo Nordisk manufactures and markets pharmaceutical products and services that make a significant difference to patients, the medical profession and society. With headquarters in Denmark, Novo Nordisk employs more than 29,000 employees in 81 countries, and markets its products in 179 countries. Novo Nordisk's B shares are listed on the stock exchanges in Copenhagen and London. Its ADRs are listed on the New York Stock Exchange under the symbol 'NVO'. For more information, visit

Company Announcement no 65 / 2009

This announcement was originally distributed by Hugin. The issuer is solely responsible for the content of this announcement.

Copyright © Hugin AS 2009. All rights reserved.

Contact Information

  • Further information:


    Mette Kruse Danielsen
    Tel: (+45) 4442 3883
    Email Contact

    In North America:
    Sean Clements
    Tel: (+1) 609 514 8316
    Email Contact


    Mads Veggerby Lausten
    Tel: (+45) 4443 7919
    Email Contact

    Kasper Roseeuw Poulsen
    Tel: (+45) 4442 4471
    Email Contact

    In North America:
    Hans Rommer
    Tel: (+1) 609 919 7937
    Email Contact